BPI-7701, a Covalent Mutant-Selective EGFR Inhibitor, Inhibits the Growth of NSCLC Lines with EGFR Activating and T790M Resistance Mutations

被引：0
|
作者：
Wilde, Victoria L. [1 ]
Zhang, Don X. [1 ]
Peng, Jirong [1 ]
Greco, Michael N. [1 ]
Green, Michael A. [1 ]
Costanzo, Michael J. [1 ]
机构：
[1] Beta Pharma Usa Inc, Res & Dev, Princeton, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; EGFR; T790M;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-016
引用
收藏
页码：S526 / S527
页数：2
相关论文
共 50 条
  • [41] Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
    Garcia, J.
    Delherme, A.
    Geigeur, F.
    Merle, P.
    Tissot, C.
    Jones, F. S.
    Edelstein, D.
    Souquet, P-J.
    Rodriguez-Lafrasse, C.
    Couraud, S.
    Payen, L. F.
    Xu, Z.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Preclinical evaluation of E-191, a highly selective EGFR T790M inhibitor
    Xile, Liu
    Hu, Lihong
    Ding, Charles Z.
    Mao, Weifeng
    Wang, Liqing
    Shi, Xiaohe
    Long, Chaofeng
    Chen, Xiaoxin
    Li, Haijun
    Liu, Xing
    Liu, Zhuowei
    CANCER RESEARCH, 2018, 78 (13)
  • [43] FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
    Wakelee, H.
    Soria, J.
    Camidge, R.
    Gadgeel, S.
    Goldman, J.
    Varga, A.
    Solomon, B.
    Papadimitrakopoulou, V.
    Kaur, P.
    Sequist, L. V.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S38 - S38
  • [44] FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
    Soria, Jean-Charles
    Sequist, Lecia V.
    Gadgeel, Shirish
    Goldman, Jonathan
    Wakelee, Heather
    Varga, Andrea
    Fidias, Panagiotis
    Wozniak, Antoinette J.
    Neal, Joel W.
    Doebele, Robert C.
    Garon, Edward B.
    Jaw-Tsai, Sarah
    Caunt, Lisa
    Kaur, Paramjit
    Rolfe, Lindsey
    Camidge, D. Ross
    Allen, Andrew
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S141 - S142
  • [45] Selective pressure for the EGFR T790M resistance mutation may be different for different EGFR tyrosine kinase inhibitors
    Chmielecki, Juliann
    Pietanza, Maria C.
    Kris, Mark
    Miller, Vincent
    Pao, William
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S250 - S250
  • [46] Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients with NSCLC Harboring EGFR Mutations
    Okura, N.
    Yamada, T.
    Yoshimura, A.
    Takeda, T.
    Kubota, Y.
    Shiotsu, S.
    Hiranuma, O.
    Uchino, J.
    Takayama, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S897 - S898
  • [47] First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)
    Sequist, Lecia V.
    Soria, Jean-Charles
    Gadgeel, Shirish M.
    Wakelee, Heather A.
    Camidge, D. Ross
    Varga, Andrea
    Solomon, Benjamin J.
    Papadimitrakopoulou, Vassiliki
    Jaw-Tsai, Sarah S.
    Caunt, Lisa
    Kaur, Paramjit
    Rolfe, Lindsey
    Allen, Andrew R.
    Goldman, Jonathan Wade
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)
    Cheema, P.
    Passaro, A.
    Martin, C.
    Tiseo, M.
    Park, K.
    Chang, G.
    Hu, Y.
    Cho, B. C.
    Miranda, M.
    Fernandes, A.
    Freitas, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S854 - S854
  • [49] TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
    Ito, Kimihiro
    Nishio, Makoto
    Kato, Masanori
    Murakami, Haruyasu
    Aoyagi, Yoshimi
    Ohe, Yuichiro
    Okayama, Takashige
    Hashimoto, Akihiro
    Ohsawa, Hirokazu
    Tanaka, Gotaro
    Nonoshita, Katsumasa
    Ito, Satoru
    Matsuo, Kenichi
    Miyadera, Kazutaka
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) : 920 - 928
  • [50] AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC
    Rivera, Victor M.
    Wang, Frank
    Anjum, Rana
    Zhang, Sen
    Squillace, Rachel
    Keats, Jeffrey
    Miller, David
    Ning, Yaoyu
    Wardwell, Scott D.
    Moran, Lauren
    Miret, Juan
    Narasimhan, Narayana
    Dalgarno, David
    Clackson, Tim
    Shakepeare, William C.
    CANCER RESEARCH, 2012, 72
12345